米氮平治疗抑郁症临床开放研究

An clinical open study of mirtazapine in the treatment of depression

目的评价米氮平治疗抑郁症的临床疗效及安全性。方法对187例抑郁症患者应用米氮平治疗，观察8w。治疗前后采用汉密顿抑郁量表与汉密顿焦虑量表评定临床疗效，副反应量表评定不良反应。结果治疗8w末临床治愈率为64．7％，总有效率为89．3％；治疗后汉密顿抑郁量表和汉密顿焦虑量表评分均较治疗前显著下降（P〈0．01），减分率分别为76．4％、78．1％，不良反应发生率为55％，较轻微，多出现在治疗初期，随着治疗时间的延续均可自行缓解。结论米氮平能有效缓解抑郁和焦虑症状，起效迅速，不良反应轻微，安全性高，依从性好。

Objective To assess the clinical efficacy and safety of mirtazapine in the treatment of depression. Methods 187 depression patients were treated with mirtazapine orally for 8 weeks. Before and after treatment, clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA） and adverse reactions with the Treatment Emergent Symptom Scale（TESS）. Results Clinical cure and total effective rate was 64.7% and 89.3% respectively at the end of the 8^th week. After treatment, scores of the HAMD and HAMA lowered more significantly compared with pretreatment （P〈0.01）, score-decrement rates of the HAMD and HAMA were 76.4% and 78.1% respectively; total incidence of adverse reactions was 23%, adverse reactions were mild, emerged mostly at initial stage of treatment and remitted spontaneously along with time of therapy lasting. Conclusion Mirtazaping can effectively relieves depression and anxiety symptoms, acts rapidly and has mild adverse reactions, higher safety and better compliance.